Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2140023 for negative symptoms of schizophrenia
NCT01052103Phase 2Completed
- Sponsor
- Denovo Biopharma
- Start
- Jan 2010
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of pomaglumetad methionil in schizophrenia, sponsored by Denovo Biopharma. Started Jan 2010; status: completed.
02
Drugs
pomaglumetad methionil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01052103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01052103.